|
US5164410A
(en)
|
1988-01-09 |
1992-11-17 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
PH26256A
(en)
*
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
US5180738A
(en)
|
1988-09-01 |
1993-01-19 |
Takeda Chemical Industries |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
EP0682020A1
(en)
|
1988-09-01 |
1995-11-15 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives useful as angiogenesis inhibitors
|
|
ATE87623T1
(de)
|
1989-03-06 |
1993-04-15 |
Takeda Chemical Industries Ltd |
6-epifumagillole, ihre herstellung und ihre verwendung.
|
|
US5288722A
(en)
|
1989-03-06 |
1994-02-22 |
Takeda Chemical Industries, Ltd. |
6-amino-6-desoxyfumagillols, production and use thereof
|
|
US5290807A
(en)
|
1989-08-10 |
1994-03-01 |
Children's Medical Center Corporation |
Method for regressing angiogenesis using o-substituted fumagillol derivatives
|
|
US6017954A
(en)
|
1989-08-10 |
2000-01-25 |
Children's Medical Center Corp. |
Method of treating tumors using O-substituted fumagillol derivatives
|
|
EP0415294A3
(en)
|
1989-08-31 |
1991-06-12 |
Takeda Chemical Industries, Ltd. |
Cyclohexanol derivatives, production and use thereof
|
|
TW282399B
(enExample)
|
1990-05-25 |
1996-08-01 |
Takeda Pharm Industry Co Ltd |
|
|
ATE205092T1
(de)
|
1992-01-30 |
2001-09-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
|
|
EP0602586B1
(en)
|
1992-12-16 |
1997-06-04 |
Takeda Chemical Industries, Ltd. |
Stable pharmaceutical composition of fumagillol derivatives
|
|
UA41446C2
(uk)
|
1995-03-27 |
2001-09-17 |
Санофі - Сінтелабо |
Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
|
|
CA2234401A1
(en)
|
1995-10-11 |
1997-04-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Vascular permeation inhibitor
|
|
EP0799616A1
(en)
|
1996-04-01 |
1997-10-08 |
Takeda Chemical Industries, Ltd. |
Oral composition comprising a fumagillol derivative
|
|
AU3968597A
(en)
|
1996-08-02 |
1998-02-25 |
Children's Medical Center Corporation |
Method of regulating the female reproductive system through angiogenesis inhibitors
|
|
US6281245B1
(en)
|
1996-10-28 |
2001-08-28 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
|
US6207704B1
(en)
|
1997-06-09 |
2001-03-27 |
Massachusetts Institute Of Technology |
Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
|
|
US6306819B1
(en)
|
1997-10-31 |
2001-10-23 |
Massachusetts Institute Of Technology |
Method for regulating size of vascularized normal tissue
|
|
US6242494B1
(en)
|
1998-05-01 |
2001-06-05 |
Abbott Laboratories |
Substituted β-amino acid inhibitors of methionine aminopeptidase-2
|
|
KR100357542B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
푸마질롤 유도체 및 그 제조방법
|
|
KR100357541B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
5-데메톡시 푸마질롤 유도체 및 그 제조방법
|
|
KR100293504B1
(ko)
|
1998-06-05 |
2001-07-12 |
김윤 |
서방형전립선염치료제조성물
|
|
JP2000116337A
(ja)
|
1998-10-09 |
2000-04-25 |
Nippon Shokuhin Kako Co Ltd |
ペットフード
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
PL351470A1
(en)
|
1999-04-28 |
2003-04-22 |
Aventis Pharma Gmbh |
Tri-aryl acid derivatives as ppar receptor ligands
|
|
EP1223932A4
(en)
|
1999-10-01 |
2003-01-15 |
Smithkline Beecham Corp |
COMPOUNDS AND METHODS
|
|
WO2001078723A1
(en)
|
2000-04-12 |
2001-10-25 |
Smithkline Beecham Corporation |
Compounds and methods
|
|
US6323228B1
(en)
|
2000-09-15 |
2001-11-27 |
Abbott Laboratories |
3-substituted indole angiogenesis inhibitors
|
|
PE20020376A1
(es)
|
2000-09-29 |
2002-05-13 |
Abbott Lab |
Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
AU3947902A
(en)
|
2000-11-01 |
2002-06-03 |
Praecis Pharm Inc |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
EP1379241A1
(en)
|
2001-03-29 |
2004-01-14 |
SmithKline Beecham Corporation |
Compounds and methods
|
|
US20020183242A1
(en)
|
2001-04-11 |
2002-12-05 |
Jack Henkin |
Peptide antiangiogenic drugs
|
|
DE60233420D1
(de)
|
2001-09-27 |
2009-10-01 |
Equispharm Co Ltd |
Fumagillolderivate und verfahren zu deren herstellung
|
|
US6803382B2
(en)
|
2001-11-09 |
2004-10-12 |
Galderma Research & Development, S.N.C. |
Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
|
|
KR100451485B1
(ko)
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6877863B2
(en)
|
2002-06-12 |
2005-04-12 |
Silicon Optix Inc. |
Automatic keystone correction system and method
|
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
|
US7030262B2
(en)
|
2002-08-06 |
2006-04-18 |
Abbott Laboratories |
3-Amino-2-hydroxyalkanoic acids and their prodrugs
|
|
US20040067266A1
(en)
|
2002-10-07 |
2004-04-08 |
Toppo Frank R. |
Weight loss compound
|
|
US20040157836A1
(en)
|
2002-10-08 |
2004-08-12 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US7491718B2
(en)
|
2002-10-08 |
2009-02-17 |
Abbott Laboratories |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
|
EP1699812A2
(en)
|
2003-12-29 |
2006-09-13 |
Praecis Pharmaceuticals Inc. |
Inhibitors of methionine aminopeptidase-2 and uses thereof
|
|
KR100552043B1
(ko)
|
2004-02-28 |
2006-02-20 |
주식회사종근당 |
푸마질롤 유도체를 포함하는 비만치료용 조성물
|
|
JP2008505176A
(ja)
|
2004-06-30 |
2008-02-21 |
コンビナトアールエックス インコーポレーティッド |
代謝障害を治療するための方法および試薬
|
|
WO2006010498A2
(en)
|
2004-07-28 |
2006-02-02 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2)
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
JP2008528574A
(ja)
|
2005-01-26 |
2008-07-31 |
チョン クン ダン ファーマシューティカル コープ． |
フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
|
|
FR2886855B1
(fr)
|
2005-06-08 |
2009-07-17 |
Agronomique Inst Nat Rech |
Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
|
|
WO2006138475A2
(en)
|
2005-06-16 |
2006-12-28 |
Jenrin Discovery |
Mao-b inhibitors useful for treating obesity
|
|
JP2010531896A
(ja)
|
2007-06-26 |
2010-09-30 |
チルドレンズ メディカル センター コーポレーション |
治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
|
|
BRPI0820229A2
(pt)
*
|
2007-11-28 |
2017-05-09 |
A Stevenson Cheri |
conjugados de análogos de fumagilina biodegradáveis biocompatíveis
|
|
US8299067B2
(en)
*
|
2008-03-27 |
2012-10-30 |
Versitech Limited |
5-demethoxyfumagillol and derivatives thereof
|
|
CA2731020A1
(en)
|
2008-07-18 |
2010-01-21 |
Zafgen, Inc. |
Use of antiangiogenic fumagillins in the treatment of obesity
|
|
CN102239149B
(zh)
|
2008-10-06 |
2015-05-13 |
约翰·霍普金斯大学 |
喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
|
|
WO2010048499A1
(en)
|
2008-10-24 |
2010-04-29 |
Wake Forest University |
Platinum acridine anti-cancer compounds and methods thereof
|
|
WO2010065881A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
WO2013055385A2
(en)
|
2011-10-03 |
2013-04-18 |
Zafgen Corporation |
Methods of treating age related disorders
|
|
US20120010290A1
(en)
|
2008-12-04 |
2012-01-12 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US8642650B2
(en)
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
MX337575B
(es)
|
2009-10-09 |
2016-03-10 |
Zafgen Corp |
Compuestos de sulfona y métodos para lafabricación y uso de éstos.
|
|
JP5827239B2
(ja)
|
2010-01-08 |
2015-12-02 |
ザフゲン，インコーポレイテッド |
フマギロール型化合物並びにその製造方法及び使用方法
|
|
US8815309B2
(en)
|
2010-01-08 |
2014-08-26 |
Zafgen, Inc. |
Methods of treating a subject with benign prostate hyperplasia
|
|
US20130023513A1
(en)
|
2010-01-12 |
2013-01-24 |
Hughes Thomas E |
Methods and Compositions for Treating Cardiovascular Disorders
|
|
US20130266578A1
(en)
|
2010-04-07 |
2013-10-10 |
Thomas E. Hughes |
Methods of treating an overweight subject
|
|
WO2011150338A1
(en)
|
2010-05-27 |
2011-12-01 |
Zafgen Corporation |
Methods of treating obesity
|
|
AU2011281037B2
(en)
|
2010-07-22 |
2014-11-27 |
Zafgen, Inc. |
Tricyclic compounds and methods of making and using same
|
|
MX339201B
(es)
|
2010-10-12 |
2016-05-13 |
Zafgen Inc |
Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
|
|
PH12013500934A1
(en)
|
2010-11-09 |
2022-10-24 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
WO2012064928A1
(en)
|
2010-11-10 |
2012-05-18 |
Zafgen Corporation |
Methods and compositions for treating thyroid hormone related disorders
|
|
US20130316994A1
(en)
|
2010-11-29 |
2013-11-28 |
Zafgen, Inc. |
Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
|
|
AU2011336785A1
(en)
|
2010-11-29 |
2013-06-20 |
Zafgen, Inc |
Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol
|
|
WO2012075026A1
(en)
|
2010-11-29 |
2012-06-07 |
Zafgen Corporation |
Methods of treating obesity using an effective dose of a metap-2 inhibitor
|
|
WO2012103333A1
(en)
|
2011-01-26 |
2012-08-02 |
Zafgen Corporation |
Tetrazole compounds and methods of making and using same
|
|
KR101875988B1
(ko)
*
|
2011-03-08 |
2018-07-06 |
자프겐 인크. |
옥사스피로[2.5]옥탄 유도체 및 유사체
|
|
SG194812A1
(en)
|
2011-05-06 |
2013-12-30 |
Zafgen Inc |
Partially saturated tricyclic compounds and methods of making and using same
|
|
CN103748094B
(zh)
|
2011-05-06 |
2016-06-29 |
扎夫根股份有限公司 |
三环磺酰胺化合物及其制备和使用方法
|
|
US9242997B2
(en)
|
2011-05-06 |
2016-01-26 |
Zafgen, Inc. |
Tricyclic pyrazole sulphonamide compunds and methods of making and using same
|
|
WO2013033430A1
(en)
|
2011-09-02 |
2013-03-07 |
Wake Forest School Of Medicine |
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
|
|
BR112014017673A8
(pt)
|
2012-01-18 |
2017-07-11 |
Zafgen Inc |
Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
|
|
WO2013109735A1
(en)
|
2012-01-18 |
2013-07-25 |
Zafgen, Inc. |
Tricyclic sulfone compounds and methods of making and using same
|
|
WO2013169727A1
(en)
|
2012-05-07 |
2013-11-14 |
Zafgen, Inc. |
Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
|
|
EP2846792B1
(en)
|
2012-05-08 |
2018-08-15 |
Zafgen, Inc. |
Treating hypothalamic obesity with metap2 inhibitors
|
|
WO2013169860A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Zafgen, Inc. |
Fumigillol type compounds and methods of making and using same
|
|
US9597309B2
(en)
|
2013-03-14 |
2017-03-21 |
Zafgen, Inc. |
Methods of treating renal disease and other disorders
|
|
AR105671A1
(es)
*
|
2015-08-11 |
2017-10-25 |
Zafgen Inc |
Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
|